LC-UV method to assay raloxifene hydrochloride in rat plasma and its application to a pharmacokinetic study
AUTOR(ES)
Fontana, Márcia Camponogara
FONTE
Braz. J. Pharm. Sci.
DATA DE PUBLICAÇÃO
30/09/2019
RESUMO
A specific, precise, and accurate LC-UV method was developed and validated to assay raloxifene hydrochloride in rat plasma. Raloxifene was analyzed after liquid-liquid extraction and quantified by reversed phase liquid chromatography (C18 column) using acetonitrile and ammonium acetate buffer 0.05 M (pH 4.0) as mobile phase at a flow rate of 1 mL.min-1 and UV detection at 287 nm. Retention times of raloxifene and internal standard (dexamethasone) were approximately 11 min and 14 min, respectively. Linearity was checked for a concentration range between 25 ng.mL-1 and 1000 ng.mL-1. Intra- and inter-day precision had relative standard deviation lower than 10% and 15%, respectively. Recovery from plasma was higher than 90%. Accuracy values were 98.21%, 99.70%, and 102.70% for lower, medium, and upper limits of quantification, respectively. Limit of quantification was 25 ng.mL-1. Drug stability was analyzed at room temperature using plasma kept in a freezer at -80 °C for 45 days after processing for 6 h and three freeze-thaw cycles. The advantages of the method developed include stability under different conditions and low limit of quantification. Its applicability was confirmed by the analysis of raloxifene levels in plasma samples in a designed pharmacokinetic study in rats after intravenous administration (5 mg.kg-1).
Documentos Relacionados
- Development and application of lc-uv method for the quantification of the anti-inflammatory thiazolidinone pg15 in rat plasma
- Development and application of LC-UV method for the quantification of the anti-inflammatory thiazolidinone PG15 in rat plasma
- Set-up of a method using LC-UV to assay mometasone furoate in pharmaceutical dosage forms
- Citalopram Hydrobromide: degradation product characterization and a validated stability-indicating LC-UV method
- Development and validation of an LC-UV method for quantification of a new thiazolidinedione (LPSF/AC-23) with antitumor activity in rat plasma